|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CYREN |
Gene summary for CYREN |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CYREN | Gene ID | 78996 |
| Gene name | cell cycle regulator of NHEJ | |
| Gene Alias | C7orf49 | |
| Cytomap | 7q33 | |
| Gene Type | protein-coding | GO ID | GO:0002200 | UniProtAcc | Q9BWK5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 78996 | CYREN | S014 | Human | Liver | HCC | 7.27e-36 | 9.45e-01 | 0.2254 |
| 78996 | CYREN | S015 | Human | Liver | HCC | 3.31e-28 | 1.06e+00 | 0.2375 |
| 78996 | CYREN | S016 | Human | Liver | HCC | 4.96e-28 | 7.31e-01 | 0.2243 |
| 78996 | CYREN | S027 | Human | Liver | HCC | 4.81e-08 | 7.00e-01 | 0.2446 |
| 78996 | CYREN | S028 | Human | Liver | HCC | 2.95e-24 | 8.53e-01 | 0.2503 |
| 78996 | CYREN | S029 | Human | Liver | HCC | 1.31e-19 | 7.31e-01 | 0.2581 |
| 78996 | CYREN | PTC01 | Human | Thyroid | PTC | 1.09e-02 | 9.68e-02 | 0.1899 |
| 78996 | CYREN | PTC05 | Human | Thyroid | PTC | 4.70e-03 | 1.52e-01 | 0.2065 |
| 78996 | CYREN | PTC06 | Human | Thyroid | PTC | 3.41e-10 | 2.37e-01 | 0.2057 |
| 78996 | CYREN | PTC07 | Human | Thyroid | PTC | 5.11e-12 | 2.40e-01 | 0.2044 |
| 78996 | CYREN | ATC09 | Human | Thyroid | ATC | 1.77e-08 | 3.43e-01 | 0.2871 |
| 78996 | CYREN | ATC12 | Human | Thyroid | ATC | 4.25e-14 | 3.11e-01 | 0.34 |
| 78996 | CYREN | ATC13 | Human | Thyroid | ATC | 5.96e-08 | 1.48e-01 | 0.34 |
| 78996 | CYREN | ATC1 | Human | Thyroid | ATC | 4.49e-08 | 3.69e-01 | 0.2878 |
| 78996 | CYREN | ATC2 | Human | Thyroid | ATC | 9.20e-14 | 7.74e-01 | 0.34 |
| 78996 | CYREN | ATC4 | Human | Thyroid | ATC | 1.37e-20 | 4.26e-01 | 0.34 |
| 78996 | CYREN | ATC5 | Human | Thyroid | ATC | 1.29e-07 | 1.74e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:200102026 | Thyroid | ATC | regulation of response to DNA damage stimulus | 121/6293 | 219/18723 | 3.22e-11 | 1.08e-09 | 121 |
| GO:000628211 | Thyroid | ATC | regulation of DNA repair | 68/6293 | 130/18723 | 8.19e-06 | 8.27e-05 | 68 |
| GO:200102114 | Thyroid | ATC | negative regulation of response to DNA damage stimulus | 46/6293 | 81/18723 | 1.51e-05 | 1.41e-04 | 46 |
| GO:200077911 | Thyroid | ATC | regulation of double-strand break repair | 45/6293 | 85/18723 | 1.83e-04 | 1.24e-03 | 45 |
| GO:000630212 | Thyroid | ATC | double-strand break repair | 110/6293 | 251/18723 | 4.48e-04 | 2.65e-03 | 110 |
| GO:00510531 | Thyroid | ATC | negative regulation of DNA metabolic process | 57/6293 | 125/18723 | 3.47e-03 | 1.55e-02 | 57 |
| GO:00063031 | Thyroid | ATC | double-strand break repair via nonhomologous end joining | 33/6293 | 66/18723 | 4.27e-03 | 1.80e-02 | 33 |
| GO:20010321 | Thyroid | ATC | regulation of double-strand break repair via nonhomologous end joining | 17/6293 | 29/18723 | 4.95e-03 | 2.03e-02 | 17 |
| GO:0045738 | Thyroid | ATC | negative regulation of DNA repair | 19/6293 | 36/18723 | 1.37e-02 | 4.77e-02 | 19 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |